Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2CNS 2Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1

Interventions

Rituximab 169Cyclophosphamide 158fludarabine 76Lenalidomide 73Vincristine 70fludarabine phosphate 63Etoposide 59Doxorubicin 56Prednisone 54venetoclax 49Cytarabine 48Dexamethasone 43Filgrastim 39Peripheral Blood Stem Cell Transplantation 38Methotrexate 38Bendamustine Hydrochloride 38ibrutinib 37obinutuzumab 36Gemcitabine 31pembrolizumab 27Melphalan 27Bortezomib 27Alemtuzumab 25Radiotherapy 23Nivolumab 21Carboplatin 21Tacrolimus 20Granulocyte Colony-Stimulating Factor 20Busulfan 20Whole-Body Irradiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × RG7388 × Lymphoid × Clear all
NCT04029688 2024-12-20

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Hoffmann-La Roche

Phase 1/2 Terminated
38 enrolled 34 charts
CNSLymphoidOther hematologic neoplasm

Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03135262 2021-12-07

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Hoffmann-La Roche

Phase 1/2 Terminated
29 enrolled 18 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02624986 2020-05-18

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Hoffmann-La Roche

Phase 1/2 Terminated
25 enrolled 21 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡